AI
NAUT icon

ArchPoint Investors’s Nautilus Biotechnolgy NAUT Stock Holding History

ArchPoint Investors’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-622,409
Closed -$451K – 74
2025
Q2 		$451K Buy
622,409
+16,276
+3% +$12.2K 0.13% 56
2025
Q1 		$522K Hold
606,133
– – 0.17% 53
2024
Q4 		$1.02M Sell
606,133
-8,138
-1% -$19.5K 0.33% 46
2024
Q3 		$1.75M Hold
614,271
– – 0.58% 37
2024
Q2 		$1.44M Buy
+614,271
New +$1.6M 0.54% 43
2023
Q4 		– Sell
-1,449,551
Closed -$4.58M – 55
2023
Q3 		$4.58M Hold
1,449,551
– – 1.75% 13
2023
Q2 		$5.61M Hold
1,449,551
– – 2.17% 13
2023
Q1 		$4.02M Hold
1,449,551
– – 1.75% 13
2022
Q4 		$2.61M Hold
1,449,551
– – 1.24% 18
2022
Q3 		$3.07M Hold
1,449,551
– – 1.25% 19
2022
Q2 		$3.9M Hold
1,449,551
– – 1.55% 18
2022
Q1 		$6.29M Hold
1,449,551
– – 2.17% 12
2021
Q4 		$7.51M Buy
+1,449,551
New +$7.76M 2.23% 12

Other funds holding NAUT

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ArchPoint Investors's NAUT Position: Q3 2025 in Review

ArchPoint Investors sold out of Nautilus Biotechnolgy (NAUT) in Q3 2025, closing a stake of 622,409 shares — an estimated $451K sold.

ArchPoint Investors first reported a position in NAUT in Q4 2021 and held it in 13 quarters. The position peaked at $7.51M in Q4 2021. 68 funds tracked by Wall St. Rank hold NAUT as of Q3 2025.

  • ArchPoint Investors reported no remaining Nautilus Biotechnolgy position as of Q3 2025 after selling out during the quarter.
  • ArchPoint Investors sold 622,409 Nautilus Biotechnolgy shares in Q3 2025, an estimated $451K.
  • ArchPoint Investors first reported a position in Nautilus Biotechnolgy in Q4 2021 and held it in 13 quarters.
  • ArchPoint Investors's Nautilus Biotechnolgy position peaked at $7.51M in Q4 2021.
  • 68 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q3 2025.

Based on ArchPoint Investors's 13F filing for Q3 2025, filed 12 Nov 2025.